Index by author

December 01, 2016; Volume 83,Issue 12

  1. Abdelghany, Mahmoud

    1. Minocycline-induced hyperpigmentation
      Mahmoud Abdelghany, MD and Alan J. Kivitz, MD
      Cleveland Clinic Journal of Medicine December 2016, 83 (12) 876-877; DOI: https://doi.org/10.3949/ccjm.83a.16058

      The patient presented with extensive bluish skin discoloration that had started 1 year earlier as a small area and then spread.

  2. Alnuaimat, Hassan

    1. Do patients with submassive pulmonary embolism benefit from thrombolytic therapy?
      Do patients with submassive pulmonary embolism benefit from thrombolytic therapy?
      Ali Ataya, MD, Jessica Cope, PharmD, Abbas Shahmohammadi, MD and Hassan Alnuaimat, MD
      Cleveland Clinic Journal of Medicine December 2016, 83 (12) 923-932; DOI: https://doi.org/10.3949/ccjm.83a.15116

      The risk of hemorrhage is signifi cant, and the benefi t is unclear. A one-treatment-for-all approach cannot be applied.

  3. Alraiyes, Abdul Hamid

    1. When should an indwelling pleural catheter be considered for malignant pleural effusion?
      Abdul Hamid Alraiyes, MD, FCCP, Kassem Harris, MD, FCCP and Thomas R. Gildea, MD, MS, FCCP
      Cleveland Clinic Journal of Medicine December 2016, 83 (12) 891-894; DOI: https://doi.org/10.3949/ccjm.83a.15075

      Consider catheter placement if symptoms and effusions recur or if pleurodesis fails.

  4. Alviar, Carlos L.

    1. Thrombolysis in submassive pulmonary embolism: Finding the balance
      Carlos L. Alviar, MD and Gustavo A. Heresi, MD
      Cleveland Clinic Journal of Medicine December 2016, 83 (12) 933-936; DOI: https://doi.org/10.3949/ccjm.83a.16099

      In massive pulmonary embolism, thrombolytic therapy is usually indicated; in submassive cases the decision is not so clear.

  5. Ataya, Ali

    1. Do patients with submassive pulmonary embolism benefit from thrombolytic therapy?
      Do patients with submassive pulmonary embolism benefit from thrombolytic therapy?
      Ali Ataya, MD, Jessica Cope, PharmD, Abbas Shahmohammadi, MD and Hassan Alnuaimat, MD
      Cleveland Clinic Journal of Medicine December 2016, 83 (12) 923-932; DOI: https://doi.org/10.3949/ccjm.83a.15116

      The risk of hemorrhage is signifi cant, and the benefi t is unclear. A one-treatment-for-all approach cannot be applied.

Back to top

In this issue